摘要
目的探讨氯雷他定联合布地奈德气雾剂治疗嗜酸粒细胞性支气管炎的临床疗效。方法 2010年1月～2013年12月来本院治疗的80例嗜酸粒细胞性支气管炎患者按随机数字表分成观察组45例,对照组35例;对照组仅给予布地奈德气雾剂2次,早晚各1次,400μg/次;观察组给予布地奈德气雾剂的基础上联合使用氯雷他定片10 mg,每晚睡前一次口服。两组均连续治疗4周,治疗后对咳嗽症状的评分、诱导痰嗜酸粒细胞百分比的比较和观察,并作统计学分析。结果治疗后3 d咳嗽症状的控制的比较两组差异具有统计学意义,但7 d后以及4周后两组差异无统计学意义。两组患者的诱导痰嗜酸粒细胞百分比比较差异无统计学意义。结论雷他定联合布地奈德气雾剂治疗嗜酸粒细胞性支气管炎能迅速改善患者症状,适合在临床上推广。
Objective To investigate the clinical efficacy of loratadine and budesonide aerosol in the treatment of eosinophilic bronchitis. Methods From January 2010 to December 2013, 80 cases of eosinophilic bronchitis in our hospital were randomly divided into observation group（45 cases）, control group（35 cases）; the control group was given budesonide aerosol 2 times, sooner or later each time, 400 μg/ times; the observation group was given budesonide aerosol based on the combined use of chlorine loratadine 10 mg, every night before going to bed after a single oral dose. Two groups were treated for 4 weeks, after treatment to observe and compare the symptoms of cough score, induced sputum eosinophil percentage, and for statistical analysis. Results There was significant difference between the two groups was 3 days after treatment cough symptom control, but after 7 days and 4 weeks no significant difference between two groups. Induced sputum in patients of the two groups the percentage of eosinophils showed no statistical significance. Conclusion Loratadine and budesonide aerosol in the treatment of eosinophilic bronchitis can rapidly improve the symptoms of patients, suitable for promotion in clinic.
出处
《中国实用医药》
2014年第15期39-40,共2页
China Practical Medicine
